Candesartan cilexetil/pioglitazone

Drug Profile

Candesartan cilexetil/pioglitazone

Alternative Names: TCV-116/Actos; TCV-116/pioglitozone

Latest Information Update: 09 Nov 2010

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Antihypertensives; Benzimidazoles; Tetrazoles; Thiazolidinediones
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension in diabetes

Most Recent Events

  • 12 May 2010 Discontinued - Phase-III for Hypertension in diabetes in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top